×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Colorectal Cancer
Featured Content
Colorectal cancer is one of the more commonly diagnosed cancers among both men and women today. Despite the fact that it most exclusively affects older persons, colorectal cancer is continuing to be diagnosed in younger and younger patients. CURE Connections wants to answer any questions you might have when it comes to managing colorectal cancer. This program includes information as shared by an expert physician, and personal accounts from patients and their caretakers who have dealt with colorectal cancer.
Conor Killmurray
While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.
Hannah Slater
“These long-awaited trial results will change clinical practice,” lead study author Dr. Thierry André, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.
Beth Fand Incollingo
As the risk of colorectal cancer grows among those under 50, younger adults should know more about signs and screening.
Colon Cancer Coalition
People experiencing gastrointestinal symptoms or delays in colorectal cancer care should address these questions with their care team.
Ryan McDonald
The Braftovi-Erbitux combination will become the preferred second-line treatment option in treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, according to one expert.
Jessica Skarzynski
Despite the impact that COVID-19 is having on cancer treatment schedules, one expert stresses the importance of staying the course not just for an individual’s benefit, but for the health of others.
Conor Killmurray
From a woman with stage 4 colon cancer deciding to stream her wedding on Zoom to a patient with breast cancer sewing masks for at risk groups across the United States, here’s the cancer news and updates happening amid the new coronavirus pandemic.
Kristie L. Kahl
The Food and Drug Administration approved the combination use of Braftovi plus Erbitux for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation.
Ryan McDonald
Although the absolute risk for colorectal cancer is very low for young people, one expert warns the incidence is increasing.
Eric Zawacki, BSN, RN, OCN